CompletedPhase 2NCT01486849

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Cytokinetics
Principal Investigator: Jeremy Shefner, MD, PhD
State University of New York - Upstate Medical University
Intervention: CK-2017357(drug)
Enrollment: 27 enrolled
Eligibility: 18 years · All sexes
Timeline: 2011 – 2012

Study locations (11)

University of California at San Francisco, Fresno Campus, Central California Neurological Institute, Fresno, California, United States
Coordinated Clinical Research, La Jolla, California, United States
University of California at Irvine, ALS and Neuromuscular Center, Orange, California, United States
Hospital for Special Care, New Britain, Connecticut, United States
Massachusetts General Hospital, Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States
Washington University, St Louis, Missouri, United States
Cornell Faculty, Hospital for Special Surgery, New York, New York, United States
Duke University School of Medicine, Division of Neurology, Durham, North Carolina, United States
Ohio State University, Department of Neurology, Columbus, Ohio, United States
Providence ALS Center, Portland, Oregon, United States
University of Texas Health Science Center, Department of Neurology, San Antonio, Texas, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01486849 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis →

← Back to all trials